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†School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Box 1627, FI-70211 Kuopio, Finland
‡Department of Biological and Environmental Science and §Department of Chemistry, University of Jyvaskyla, P.O. Box 35, FI-40014
Jyvaskyla, Finland
∥Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, FI-00014 Helsinki,
Finland
⊥Institute of Biomedicine, Faculty of Medicine, University of Turku, FI-20014 Turku, Finland
*S Supporting Information
ABSTRACT: Intestinal and hepatic glucuronidation by the UDP-glucuronosyltransferases (UGTs) greatly affect the
bioavailability of phenolic compounds. UGT1A10 catalyzes glucuronidation reactions in the intestine, but not in the liver.
Here, our aim was to develop selective, fluorescent substrates to easily elucidate UGT1A10 function. To this end, homology
models were constructed and used to design new substrates, and subsequently, six novel C3-substituted (4-fluorophenyl, 4-
hydroxyphenyl, 4-methoxyphenyl, 4-(dimethylamino)phenyl, 4-methylphenyl, or triazole) 7-hydroxycoumarin derivatives were
synthesized from inexpensive starting materials. All tested compounds could be glucuronidated to nonfluorescent glucuronides
by UGT1A10, four of them highly selectively by this enzyme. A new UGT1A10 mutant, 1A10-H210M, was prepared on the basis
of the newly constructed model. Glucuronidation kinetics of the new compounds, in both wild-type and mutant UGT1A10
enzymes, revealed variable effects of the mutation. All six new C3-substituted 7-hydroxycoumarins were glucuronidated faster by
human intestine than by liver microsomes, supporting the results obtained with recombinant UGTs. The most selective 4-
(dimethylamino)phenyl and triazole C3-substituted 7-hydroxycoumarins could be very useful substrates in studying the function
and expression of the human UGT1A10.
KEYWORDS: 7-hydroxycoumarin derivative, UDP-glucuronosyltransferase, in silico, fluorescence, drug metabolism
■ INTRODUCTION
The extents of absorption and first-pass metabolism in the
intestine and liver strongly affect the bioavailability of drugs and
other orally ingested xenobiotic compounds.1,2 Although
hepatic metabolism is the major determinant of first-pass
metabolism for most drugs, intestinal metabolism is critical for
the bioavailability of certain compounds, particularly those that
could be directly conjugated, like phenols and flavonoids.3−5
Such xenobiotics typically contain a nucleophilic functional
group, usually a hydroxyl group, that can accept an endogenous
conjugating moiety, particularly glucuronic acid or sulfone.
More rarely, the conjugating group is methyl, acetyl, or amino
acid.6
The UDP-glucuronosyltransferase enzymes (UGTs, EC
2.4.1.17) catalyze about 35% of the drug conjugation reactions
and are abundantly expressed among the intestinal conjugating
enzymes.4,5,7 They catalyze transfer of the glucuronic acid
moiety from UDP-glucuronic acid cofactor onto hydroxyl,
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amine, carboxylic acid, thiol, or thioacid groups of the aglycone
substrates, reactions that are commonly called glucuronidation.8
There is a significant difference in the expression profile of
individual UGTs between the intestine and liver.9−11 While
about 10 different UGTs are abundantly expressed in the liver,
only UGT1A1, UGT1A10, UGT2B7, and UGT2B17 are
expressed in the small intestine to significant amounts at the
protein level.10,12−14 Unfortunately, the high activity and
importance of the intestinal UGT1A10 was (and still is)
often underestimated due to common use of poorly active
commercial UGT1A10.13
UGT1A10 glucuronidates many drugs and xenobiot-
ics.13,15−17 Glucuronidation of estriol at the 3-OH and of
estrone could be used as a selective reaction for UGT1A10, but
the measurements require chromatographic separation of the
resulting glucuronide from the substrate.16,18 Likewise,
dopamine is a UGT1A10-selective substrate, but its low
affinity19 has limited its use to qualitative measurements
only.14 Accordingly, availability of more convenient marker
substrates for UGT1A10 would foster evaluation of glucur-
onidation reactions, particularly if the assays were easy and fast
to perform.
The interactions between substrates and xenobiotic metab-
olizing enzymes are increasingly being studied by in silico
modeling.20−23 Currently, the lack of crystal structures of the
N-terminal domain of any mammalian UGT impedes the
structure−activity relationship and mechanistic studies. UDP-
glucuronic acid binds at the C-terminal domain, which is highly
homologous among different UGTs and evolutionary con-
served. The structure of the latter domain has been solved by
X-ray crystallography.24 However, that available crystal
structure does not provide sufficient data to predict binding
of acceptor substrates, e.g., a drug molecule, as substrates bind
to the N-terminal domain, which is more variable than the C-
terminal domain among UGT enzymes. In silico models for
this domain were constructed previously,20,21 but we need
better ones in order to analyze substrate−enzyme interactions
in UGTs at the atomic level.
The hydroxyl group at C7 on the coumarin scaffold renders
the compound fluorescent and glucuronidation of this hydroxyl
abolishes the fluorescence (Figure 1).25 Substituents at
positions such as C3 or C4 of the coumarin do not quench
the 7-hydroxycoumarin derivatives’ fluorescence but modify its
intensity, depending on the substituent’s chemical nature. The
7-hydroxyl group on coumarin is also a good functional group
for glucuronidation by many UGTs. Therefore, fluorescent 7-
hydroxycoumarin derivatives provide an opportunity to design
novel fluorescent substrates for UGTs using molecular
modeling as the starting point.
In this study, we first constructed homology models for all
the human UGT enzymes of subfamily 1A and used them to
design fluorescent 7-hydroxycoumarin derivatives in silico. We
then synthesized six compounds and developed a convenient
multiwell plate assay protocol, based on fluorescence decrease,
to test their glucuronidation rate. The results led to the
identification of several 3-substituted 7-hydroxycoumarins as
selective substrates for the human UGT1A10. A UGT1A10
mutant was prepared based on the model and as a test for it.
Subsequently, glucuronidation kinetic analyses of the 3-
substituted 7-hydroxycoumarins, by wild-type and mutant
UGT1A10, were carried out using the same multiwell plate
assay protocol.
■ EXPERIMENTAL SECTION
Materials. Alamethicin, trichloroacetic acid, UDPGA
sodium salt, 7-hydroxycoumarin (99%), 7-hydroxy-(4-
trifluoromethyl)coumarin (99%), and bovine serum albumin
were from Sigma-Aldrich (Mannheim, Germany). Formic acid
(99%) and MgCl2 were from Riedel-de Haen (Vantaa,
Finland). Acetonitrile (Ultra gradient HPLC grade), methanol
(HPLC gradient grade), and glycine were from J.T. Baker
(Deventer, The Netherlands). Ethanol (≥99.5%, Etax Aa) was
from Altia (Helsinki, Finland). Water was deionized by Milli-Q
gradient A10.
Methods. Modeling. To enable structure-based design of
UGT1A10 selective substrates, all nine UGT1A-enzymes were
modeled. Sequences of human UGT1A enzymes were gathered
from the UniProt Knowledgebase at www.uniprot.org (UniProt
Consortium, 2015). The accession codes for the retrieved
UGT1As were: Q9HAW8 (1A10), O60656 (1A9), Q9HAW9
(1A8), Q9HAW7 (1A7), P19224 (1A6), P35504 (1A5),
P22310 (1A4), P35503 (1A3), and P22039 (1A1). To identify
template protein structures for homology modeling purposes,
the retrieved UGT sequences were used in blast searches
against the protein data bank (PDB) structures. Based on the
results of these searches, structures 2O6L,24 3HBF,26 3WC4,27
and 2C1Z28 were selected as templates for homology modeling.
The sequence alignment for the modeling was produced in two
steps. First a protein structure-based sequence alignment was
derived for the selected four protein structures by using Vertaa
in BODIL29 and the 2C1Z-structure as a template, since it gave
the best match for UGT1A10 and contained both the N- and
C-termini. In the second step the above listed nine UGT1A
sequences were aligned, using BODIL, against the structural
alignment, using STRMAT110 matrix30 with 40 as the gap
penalty. The alignment was adjusted for occasional variations in
sequence length and used to create models for each UGT1A as
well as in model construction that was performed using
Modeler version 9.15.31
Molecular Docking. The ligands that were selected for
docking studies were prepared by using LigPrep (version 3.3,
Schrödinger, LLC, New York, 2015). The shapes and
Figure 1. Glucuronidation of 7-hydroxycoumarin derivatives. Fluorescent 3-substituted 7-hydroxycoumarins are glucuronidated to nonfluorescent
glucuronide conjugates by UGT enzymes. The decrease in fluorescence can be measured conveniently in different kinds of experimental setups.
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electrostatic properties of the substrate binding sites of
modeling-produced UGT1A enzymes were analyzed with
Panther,32 and molecular docking was performed with
PLANTS.33
Synthesis. All the synthesis reactions were carried out using
commercial materials and reagents without further purification,
unless otherwise noted. Reaction mixtures were heated using
the CEM Discovery microwave apparatus. All reactions were
monitored by thin-layer chromatography (TLC) on silica gel
plates. 1H NMR and 13C NMR data were recorded on a Bruker
Avance 400 MHz spectrometer or Bruker Avance III 300 MHz
spectrometer. Chemical shifts are expressed in parts per million
values (ppm) and are designated as s (singlet), br s (broad
singlet), d (doublet), dd (double douplet), t (triplet). Coupling
constants (J) are expressed as values in hertz (Hz). The mass
spectra were recorded using Micromass LCT ESI-TOF
equipment. Elemental analyses were done with Elementar
Vario EL III elemental analyzer. All compounds tested present
more than 95% purity.
General Procedure for the Synthesis of Coumarin
Derivatives. The coumarin derivatives 1−6 were synthesized
using the Perkin-Oglialor condensation reaction (Scheme 1).
The method was developed from the previously published
procedures and transferred to a microwave reactor.34
Typical procedure: A mixture of salicylaldehyde derivative (2
mmol) and phenyl acetic acid derivative (2.1 mmol), acetic acid
anhydride (0.6 mL), and triethylamine (0.36 mL) was placed in
a microwave reactor tube and heated at 100−170 °C in the
microwave apparatus for 10−20 min. After cooling, 2 mL of
10% NaHCO3 solution was added, and the precipitate was
filtered, dried, and recrystallized from EtOH/H2O or acetone/
H2O mixture. The acetyl group(s) were removed by treating
the compound with MeOH/NaOH(aq) solution for 30−60
min at rt. The solution was acidified with HCl (aq), and the
precipitate was filtered and recrystallized if needed. Exper-
imental data for 7-acetoxy-3-(4-fluorophenyl)-2H-chromen-
2one, 7-hydroxy-3-(4-fluorophenyl)-2H-chromen-2-one (1),
7-acetoxy-3-(4-acetoxyphenyl)-2H-chromen-2one, 7-hydroxy-
3-(4-hydroxyphenyl)-2H-chromen-2one (2), and 7-acetoxy-3-
(4-methoxyphenyl)coumarin, 7-hydroxy-3-(4-methoxyphenyl)-
coumarin (3) were already published elsewhere.34
7-Hydroxy-3-(4-(dimethylamino)phenyl)-2H-chromen-2-
one (4).35 In the first step, 7-acetoxy-3-(4-(dimethylamino)-
phenyl)-2H-chromen-2one was obtained. Yield: 70%. 1H NMR
(400 MHz, DMSO-d6) δ: 2.31 (s, 3H, CH3CO), 2.95 (s, 6H,
(CH3)2N−), 6.77 (d, J3 = 9.0 Hz, 2H, H-2′, H-6′), 7.14 (dd, J3
= 8.4 Hz, J4 = 2.2 Hz, 1H, H-5), 7.26 (d, J4 = 2.2 Hz, 1H, H-8),
7.63 (d, J3 = 9.0 Hz, 2H, H-3′, H-5′) 7.76 (d, J3 = 8.5 Hz, 1H,
H-5), 8.11 (s, 1H, H-4). 13C NMR (100.6 MHz, DMSO-d6) δ:
20.85, 39.84, 109.44, 111.58, 117.76, 118.57, 121.57, 126.00,
128.82, 129.11, 136.46, 150.45, 151.90, 152.77, 159.74, 168.85.
In the second step, 7-hydroxy-3-(4-(dimethylamino)phenyl)-
2H-chromen-2one (4) was obtained. Yield: 85% yellow solid.
1H NMR (400 MHz, DMSO-d6) δ: 2.94 (s, 6H, (CH3)2N-),
6.72 (d, J4 = 2.3 Hz, 1H, H-8), 6.75 (d, J3 = 9.0 Hz, 2H, H-2′,
H-6′), 6.79 (dd, J3 = 8.4 Hz, J4 = 2.3 Hz, 1H, H-5),), 7.55 (d, J3
= 8.5 Hz, 1H, H-5), 7.58 (d, J3 = 9.0 Hz, 2H, H-3′, H-5′), 7.99
(s, 1H, H-4). 13C NMR (100.6 MHz, DMSO-d6) δ: 39.92,
101.59, 112.33, 113.16, 122.30, 122.32, 129.34, 137.83, 150.07,
154.27, 160.30, 160.41. ESI-MS: m/z (rel abund) 304 [M +
Na+]. Anal. Calcd for C17H15N1O3: C, 72.58; H, 5.37; N, 4.98.
Found: C, 72.45; H, 5.40; N, 5.15.
7-Hydroxy-3-(p-tolyl)-2H-chromen-2-one (5).36 In the first
step, 7-acetoxy-3-(p-tolyl)-2H-chromen-2one was obtained.
Yield: 70%. 1H-NMR (300 MHz, d6-DMSO) δ: 2.34 (s, 3H,
CH3-Ph), 6.75 (d, J
4 = 2.2 Hz, 1H, H-8), 6.81 (dd, J3 = 8.5 Hz,
J4 = 2.2 Hz, 1H, H-6), 7.23 (d, J3 = 8.0 Hz, 2H, H-2′, H-6′),
7.58 (d, J3 = 8.5 Hz, 1H, H-5), 7.59 (d, J3 = 8.1 Hz, 2H, H-3′,
H5′), 8.10 (s, 1H, H-4), 10.54 (s, 1H, Ph-OH). δ: 2.32 (s, 3H,
CH3CO), 2.35 (s, 3H, CH3−Ph), 7.17 (dd, J3 = 8.4 Hz, J4 = 2.2
Hz 1H, H-6), 7.27 (d, J3 = 8.0 Hz, 2H, H-2′, H-6′), 7.29 (d, J4
= 2.2 Hz, 1H, H-8), 7.63 (d, J3 = 8.2 Hz, 2H, H-3′, H-5′) 7.80
(d, J3 = 8.5 Hz, 1H, H-5), 8.21 (s, 1H, H-4). 13C NMR (100.6
MHz, DMSO-d6) δ: 20.77, 20.82, 109.56, 117.37, 118.66,
125.99, 128.25, 128.76, 129.30, 131.60, 138.09, 139.37, 152.51,
153.28, 159.47, 168.74.
In the second step, 7-hydroxy-3-(p-tolyl)-2H-chromen-2one
(5) was obtained. Yield: 85% brownish solid. 1H NMR (300
MHz, DMSO-d6) δ.
13C NMR (75 MHz, DMSO-d6) δ: 20.74,
101.65, 112.01, 113.30, 122.07, 128.04, 128.69, 129.80, 132.14,
137.37, 140.38, 154.77, 160.05, 161.05. ESI-MS: m/z (rel
abund) 275 [M + Na+]. Anal. Calcd for C16H12O3: C, 76.18; H,
4.79. Found: C, 75.95; H, 4.83.
7-Hydroxy-3-(1H-1,2,4-triazol-1-yl)-2H-chromen-2-one (6).
In the first step, 2-oxo-3-(1H-1,2,4-triazol-1-yl)-2H-chromen-7-
yl acetate was obtained. Yield: 65% slightly brown solid. 1H
NMR (400 MHz, DMSO-d6) δ: 2.33 (s, 3H, CH3-CO), 7.27
(dd, J3 = 8.5 Hz, J4 = 2.2 Hz, 1H, H-6), 7.44 (d, J4 = 2.2 Hz 1H,
H-8), 7.98 (d, J3 = 8.5 Hz, 1H, H-5), 8.33 (s, 1H, H-3′), 8.61 (s,
1H, H-4), 9.20 (s, 1H, H-5′). 13C NMR (100.6 MHz, DMSO-
d6) δ: 20.87, 110.02, 116.19, 119.50, 123.04, 130.10, 131.81,
144.40, 152.06, 152.21, 153.12, 155.73, 168.76. FT-IR (KBr,
cm−1): 3416, 1723, 1617, 1208, 1129. Mp: 190−192 °C. ESI-
MS: m/z (rel abund): calcd for [M + Na+] 294.0485, measured
294.0499, Δ = −1.4 mDa.
In the second step, the acetyl group was removed by treating
the above-mentioned compound with MeOH/K2CO3 solution.
Yield: 92% slightly brown solid. 1H NMR (400 MHz, DMSO-
d6) δ: 6.85 (d, J
4 = 2.3 Hz, 1H, H-8), 6.90 (dd, J3 = 8.5 Hz, J4 =
2.3 Hz, 1H, H-6), 7.74 (d, J3 = 8.6 Hz, 1H, H-5), 8.27 (s, 1H,
H-3′), 8.49 (s, 1H, H-4), 9.10 (s, 1H, H-5′), 10.83 (br s, 1H,
OH). 13C NMR (100.6 MHz, DMSO-d6) δ: 102.07, 110.42,
114.23, 119.72, 130.70, 134.11, 144.24, 151.78, 153.96, 156.37,
162.01. FT-IR (ATR, cm−1): 1724, 1623, 1511, 1328, 1129 811.
Mp: > 312 °C dec. ESI-MS: m/z (rel abund) calcd for [M −
H+] 228.0415, measured 228.0408. Δ = 0.7 mDa.
UGTs and Microsomes. Recombinant human UGTs 1A1,
1A3, 1A6, 1A7, 1A8, 1A9, 1A10, 2A1, 2A2, 2A3, 2B4, 2B10,
Scheme 1. General Procedure for the Synthesis of Coumarin Derivatives
Molecular Pharmaceutics Article
DOI: 10.1021/acs.molpharmaceut.7b00871
Mol. Pharmaceutics 2018, 15, 923−933
925
2B7, and 2B17 were produced, as His-tagged proteins, in
baculovirus-infected insect cells as previously described.37−39
The relative expression level of each of these recombinant
UGTs was evaluated by immunodetection, using monoclonal
antibody against the His-tag, as described elsewhere.40 A
numeric value of 1.0 was given to the expression level of
UGT1A8 and the relative expression level of each of the other
UGTs was related to this value. Normalized activities were
obtained by dividing the glucuronidation rate values by the
relative expression level of the tested UGT. In addition, UGTs
1A4, 2B10, and 2B15 were purchased from Corning Life
Sciences (New York) and are marked, in Figure 5, with a “C” to
indicate that they are commercial enzymes. The expression
levels of the UGTs in the commercial samples could not be
determined, so their protein concentration was used to
calculate the reaction rate.
A commercial HLM pool (cat no:452210, BD Gentest,
Bedford, MA) and human intestine microsomes (HIM) pool
(lot. no 1110189, XenoTech, Kansas City, KS) were purchased.
Pig liver samples were prepared from untreated female pigs that
were used for practicing surgical procedures at the University of
Kuopio (currently: University of Eastern Finland, Kuopio
campus). Other animal liver microsomes were prepared as
described previously.41 The Ethics Committee for Animal
Experiments, University of Kuopio, approved these experi-
ments.
Mutagenesis of UGT1A10. The UGT1A10 mutant 1A10-
H210 M was prepared according to the QuikChange
methodology, using the cloned UGT1A10 in pFastBac42 as a
template and the following two oligonucleotides:
1. 5′-ACTTTCAAGGAGAGAGTATGGAACATGATCGT-
GCACTTGGAGGACCATTT-3′
2. 5′- AAATGGTCCTCCAAGTGCACGATCATGTTCC-
ATACTCTCTCCTTGAAAGT-3′
The entire coding sequence of UGT1A10 in the mutant
clone was sequenced, and subsequently, recombinant baculo-
virus was prepared and used to express the mutant enzyme in
baculovirus-infected SF9 insect cells.
Absorbance and Fluorescence Spectra of C3-Sub-
stituted 7-Coumarins. The absorbance spectra of 10 μM
coumarin derivatives at 100 mM Tris−HCl pH 7.4 containing
10% dimethyl sulfoxide were measured using a Hitachi U-2000
Spectrophotometer (Tokyo, Japan). Excitation and emission
fluorescence spectra of 0.1 μM coumarin derivatives in 100 mM
Tris-HCl pH 7.4 were measured using a Shimadzu RF-5000
spectrophotofluorometer (Tokyo, Japan). The excitation
spectra was from 200 to 420 at 460 nm emission and the
emission spectra was from 400 to 600 at 390 nm excitation
(data in Supplementary Table S1 and Figures S1 and S2). The
effect of pH on fluorescence intensity was determined at 405
nm excitation and 460 nm emission, in the presence of 1.5%
trichloroacetic acid, 100 mM phosphate buffers at pH 5, 6, 7, 8,
and 9, or 1.6 M glycine−NaOH pH 10.4.
Glucuronidation Reactions. The incubation mixtures for
glucuronidation assays contained 100 mM Tris-HCl buffer pH
7.4, 2.5 mM MgCl2, 0.5 mM UDPGA, recombinant UGT, or
microsomes as the enzyme source and 0−15 μM of the test
aglycone substrate. When the incubation mixtures contained
microsomes, alamethicin was used at a final concentration of
12.5 μg/mL, but it was not included in the recombinant
enzyme assays.43 In the first experiments three negative control
samples were tested, namely (i) without the substrate 7-
hydroxycoumarin derivative, (ii) without the cofactor UDPGA,
or (iii) without the enzyme source. In subsequent experiments,
the control samples lacked the enzyme source since it gave the
highest fluorescence background. Preliminary experiments were
done under different conditions than most of the later assays,
namely in 2.5 mL of 100 mM phosphate buffer pH 7.4,
containing 500 μg pig liver microsomes, 1.0 μM compound 6
and 0.5 mM UDPGA, at room temperature. Fluorescence
spectra (excitation 200−420 nm; emission 400−600 nm) or
fluorescence decrease at 390 nm excitation and 460 nm
emission, were measured in these preliminary experiments,
using a Shimadzu RF-5000 spectrophotofluorometer.
Most of the glucuronidation assays were carried out in 96
multiwell plate format, and incubations were carried out in 100
μL and at 37 °C, in the presence of Tris−HCl buffer pH 7.4,
UDPGA, and the tested 7-hydroxycoumarin derivative, at the
indicated concentrations. Fluorescence decline in the multiwell
plate experiments was monitored every other minute, for 40
min, using an excitation filter at 405 nm and detection at 460
nm, in a Victor2 1420 Multilabel counter (PerkinElmer, Life
Sciences, Turku, Finland). The fluorescence values were
transformed into molarity using the aglycone substrates for
making the respective standard curves. Slopes of the substrate
concentration decrease per minute were calculated using linear
regression analysis, in which the linear part of the kinetic assay
indicated the glucuronidation rate. Enzyme catalyzed glucur-
onidation rate was calculated by subtracting the blank value
from the full reaction value. The intra-assay variability of the
kinetic assays was 6% when compound 6 was used as the
aglycone substrate. Kinetic analyses were also performed in the
same 96 multiwell plates format, with excitation filter at 405 nm
and detection at 460 nm, using 6−8 different substrate
concentrations per substrate and two different protein
concentrations for both the wild-type and mutant UGT1A10.
The higher concentrations, 13.5 mg/L for UGT1A10 and 12.0
mg/L for the UGT1A10 mutant, were used when the substrates
were HFC, compounds 4 and 6, whereas the lower protein
concentrations, 6.75 and 6.0 mg/L for UGT1A10 and the
mutant, respectively, were used when the substrates were
compounds 1, 2, 3, and 5.
In end-point determinations, the glucuronidation reactions
were stopped by the addition of 150 μL 1.6 M glycine-NaOH
buffer, pH 10.4, followed by fluorescence measurements at 405
nm excitation and 460 nm emission. There was a good
correlation between kinetic and end-point assays (data not
shown).
HPLC−MS Analysis of 7-Hydroxy-3-triazolecoumarin
Glucuronide. For further analysis of 7-hydroxy-3-triazolecou-
marin glucuronide, 10 μM of compound 6 were incubated in
100 μL of 100 mM Tris−HCl pH 7.4 buffer containing 5 mM
MgCl2, 1 mM UDPGA, and either 30−40 μg recombinant
UGT, 30 μg HLM, or 20 μg HIM for 1 h at 37 C. The
reactions were stopped by the addition of 300 μL of methanol
and centrifugation, and then the supernatant was divided into
two. One part, 100 μL supernatant, was mixed with 150 μL of
1.6 M glycine−NaOH pH 10.4 and subjected to fluorescence
measurements as described above for the 96-well plate. The
other part, 250 μL supernatant, was stored at −20 C until
analysis by HPLC−MS.
An Agilent 1200 Series Rapid Resolution LC System (Agilent
Technologies, Waldbronn, Germany) was used for the
chromatographic separation, equipped with a reversed-phase
C8 column (Brownlee Supra, 3 μm, 50 × 2.1 mm,
PerkinElmer). The mobile phases were (A) 0.1% aqueous
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formic acid and (B) acetonitrile. A linear gradient from 10% to
90% B in five min was applied, followed by one min isocratic
elution with 90% B and column re-equilibration, yielding a total
analysis time of nine min. The flow rate was 0.3 mL/min,
injection volume 3 μL and column oven temperature 30 °C.
For the MS detection, a Finnigan LTQ ion trap mass
spectrometer (Thermo, San Jose, CA) was used in the positive
electrospray (ESI) mode. A divert valve was used to direct
eluent flow to the waste for 1 min at the beginning and at the
end of the gradient run. The MS analysis was carried out using
the following parameters: spray voltage 4 kV, sheath gas 30
(instrument units), aux gas 15, sweep gas 3, capillary
temperature 250 °C, capillary voltage 43 V, tube lens 100 V.
The collision energy used for MS/MS was 30 V. The acquired
full scan MS range was m/z 60−600. Ions used for the
detection of the aglycone and glucuronide conjugate were m/z
230 [M + H]+ and m/z 406 [M + H + 176]+, respectively. Data
was acquired and processed using Xcalibur software package.
■ RESULTS
Modeling UGT1A Enzymes. Template structures for
homology modeling of the UGT enzymes of subfamily 1A
were selected based on sequence similarity using the blast
option in Uniprot. Structures that contained both the sugar−
nucleotide cofactor and a small aglycone molecule were
beneficial for the model, and therefore, structures (pdb-
codes) 2C1Z/X, 2O6L, 3HBF, and 3WC4 were selected. The
conserved lipophilic region that spans the endoplasmic
reticulum membrane and ends in the “cytoplasmic tail” were
excluded from the model because the focus of the model
construction was on the catalytic site and its surrounding area.
In addition, other structures outside the catalytic site of the
model, including loops and amino acid side chain conforma-
tions, were not optimized. Optimizing effords were considered
detrimental for the quality of the models as the sequence
similarity between the templates and the UGT sequences was
very low. In other words, the models were not considered to be
good enough for molecular dynamics simulations in order to
evaluate binding energy or other kinetic parameters. On the
other hand, an essential part of the model building was to
predict binding of the 7-hydroxycoumarin derivatives so that
glucuronidation will occur at the 7-hydroxyl group, and for this
purpose the models were adequate.
The homology models were used to design novel and UGT-
selective fluorescent 7-hydroxycoumarin substrate molecules,
whose fluorescence will decrease upon glucuronidation (Figure
1). Docking of the 7-hydroxycoumarin scaffolds (Figure 2A-C)
into different UGT1A models yielded several possible
conformations. One of them oriented the 7-hydroxy group
toward the bound UDP-glucuronic acid (UDPGA) cofactor at
the catalytic site, and simultaneously, the coumarin core was
optimally placed into a nearby cavity in the catalytic site (Figure
2D). In our models, the coumarin scaffold could be stabilized
through its C2-carbonyl oxygen, accepting a hydrogen bond
from Q101 in UGT1A8 (Figure 2C), UGT1A9, and UGT1A10
(Figure 2A). Even stronger stabilizing interactions could be
formed between the coumarin carbonyl at C2 and R102 of
UGT1A6 (Figure 2C). On the other hand, D103 in UGT1A1
(Figure 2B), E104 in UGT1A3 and UGT1A4, or P101 in
UGT1A7, are not capable of forming similar stabilizing
hydrogen bond interactions at this site, suggesting that the
coumarin core would not be an optimal substrate for these
UGTs. Furthermore, R103 of UGT1A7, UGT1A8, and
UGT1A9, counteracted the stabilizing interactions and partially
blocked the binding of the coumarin scaffold to these UGTs
due to its size (Figure 2C). Unlike significantly bulkier R103 of
UGT1A8 (Figure 2C), the Q103 of UGT1A10 at this site could
donate a hydrogen bond to the oxygen at position 1 of the
coumarin scaffold (Figure 2A).
Based on these homology models, there was an additional,
but variable in size, free space available in the active site of each
UGT1A enzyme, next to position 3 of the coumarin core.
When combined with the 7-hydroxycoumarin docking site
analyses (see above), this additional space was large enough in
UGT1A1 and UGT1A10 to accommodate five- or six-
membered ring substituents (Figure 2D). In contrast, a bulkier
phenylalanine (F212) is present in the UGT1A6 model at this
position, clearly hindering binding of any 3-substituted 7-
hydroxycoumarins. The properties of this binding site were
quite different also between UGT1A1 and UGT1A10. While
UGT1A1 has a hydrophobic methionine (M213) facing this
site (Figure 2B), UGT1A10 has a histidine at the
Figure 2. Docking of 7-hydroxycoumarin and its derivatives into the
UGT1A10 model. (A) Molecular docking placed the 7-hydroxycou-
marin with the 7-hydroxy facing the catalytic site formed by H37 and
UDPGA, enabling the glucuronidation reaction and the subsequent
decrease in fluorescence. (B) In UGT1A1, D103, and L106 are not
capable of forming similar beneficial interactions with the coumarin
core as the UGT1A10 model. Although N102 might be able to form
beneficial interactions with certain compounds, the cavity might not be
large enough for more sizable substitutions due to N102 and M213.
(C) UGT1A8 has otherwise the same amino acid residues aligning the
cavity as UGT1A10, except for R103. Due to its size, R103 might
impair the binding of the coumarin core. (D) 6 fills the binding cavity
(orange solvent accessible surface) of the UGT1A10 model (green
solvent accessible surface). Docking suggests that the 7-hydroxycou-
marin and 6 have a similar binding mode at their identical core. In
addition, the C3 substituent of 6 fits tightly to the additional space at
the outward facing end of the binding cavity.
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corresponding site (H210; Figure 2A). On the opposite side of
this additional space, UGT1A10 has an alanine (A100), while
UGT1A1 has an asparagine (N102) aligned to the same
position. This may mean that in UGT1A10 there is enough
space for rather large 3-substituted 7-hydroxycoumarins,
whereas UGT1A1 would have problems accommodating larger
subsitutions at this position of the 7-hydroxycoumarin scaffold.
At the other end of the UGT1As “spectrum”, UGT1A6 has a
glutamic acid (E101) aligned at the same site, which would
limit the cavity even further.
Based on docking of a virtual library into the UGT1A10
model, the most promising molecules were 7-hydroxycoumarin
Figure 3. Novel (1−6) and control 7-hydroxycoumarin and 7-hydroxy-4-trifluoromethylcoumarin (HCF) substrates of UGT1A enzymes in this
study.
Figure 4. Decrease of 7-hydroxycoumarin fluorescence during glucuronidation. Excitation and emission fluorescence spectra of 0.1 μM 7-hydroxy-3-
triazolecoumarin at 100 mM phosphate pH 7.4 buffer (panel A); decrease in 10 μM 7-hydroxy-3-triazolecoumarin fluorescence in the presence of 0.7
mg/mL pig liver microsomal protein, 0.5 mM UDPGA, 5 mM MgCl2, and 100 mM Tris-HCL pH 7.4 (panel B); effect of the amount of microsomal
protein on the decrease in fluorescence (panel C); effect of solvents and alamethicin on the decrease in fluorescence (panel D). Corresponding
results were obtained with other C7-substituted 7-hydroxycoumarin derivatives.
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derivatives with the following substituents at the C3 position: 4-
fluorophenyl (1), 4-hydroxyphenyl (2), 4-methoxyphenyl (3),
4-(dimethylamino)phenyl (4), 4-methylphenyl (5) or triazole
(6). Among these, the triazole (6) derivative could be stabilized
by H210 in UGT1A10, while the corresponding methionine in
UGT1A1 (M213) would not be able to form hydrogen bonds
with it. In contrast, the addition of a phenyl moiety to the C3-
position would allow binding by both UGT1A1 and UGT1A10,
as the hydrophobic methionine in UGT1A1 is quite an ideal
companion, while the histidine in UGT1A10 could change its
conformation according to the donor functionality, as with
triazole. Based on these observations and considerations, the six
new coumarin derivatives were designed and synthesized
(Figure 3: compounds 1-6). The selected compounds were
made from inexpensive starting materials, producing 3-
substituted coumarins with 5- or 6-membered rings.
Glucuronidation of the 3-Substituted 7-Hydroxycou-
marins. The absorbance and fluorescence spectra of
compounds 1−6 were very similar showing, however, some
differences in intensity as well as excitation and emission peaks
among them (Figure 4A, Supplementary Figures 1 and 2, and
Supplementary Table 1). The fluoresecence was pH dependent,
emitting strongly in neutral and alkaline solutions.
In the first glucuronidation experiments, the fluorescence
intensity of all of the C3-substituted 7-hydroxycoumarin
derivatives, compounds 1−6, decreased when they were
incubated in the presence of pig liver microsomes and
UDPGA in a buffer containing 100 mM Tris-HCl pH 7.4
and 5 mM MgCl2 (Figure 4B). No significant fluorescence
decrease was observed in the negative controls, namely in the
absence of either microsomes, a coumarin derivative such as 6,
or UDPGA. The fluorescence changes were linearly dependent
on the amount of microsomes (Figure 4C), indicating that the
biosynthesis of C3 substituted 7-hydroxycoumarin derivatives
to nonfluorescent glucuronide conjugates was catalyzed by one
or more UDP-glucuronosyltransferase enzymes in the micro-
somes. The presence of alamethicin increased glucuronidation
rates in this microsomal sample, whereas the addition of more
than 5% (v/v) dimethyl sulfoxide, acetonitrile, or ethanol
decreased it (Figure 4D). An example for glucuronide
formation under such incubation condition, using 6 as the
substrate, is presented in Figure S3.
The above results with 6 and pig liver microsomes suggested
that the glucuronidation rates of the new 7-hydroxycoumarin
derivatives could be accurately determined under our stand-
ardized assay conditions, using different enzyme sources.
Subsequently, the glucuronidation rates of all the new C3
substituted 7-hydroxycoumarin derivatives by nearly all the
human UGTs, including enzymes that are not commercially
available, were determined (Figure 5). For comparison and
additional controls, the glucuronidation of 7-hydroxycoumarin
and 4-(trifluoromethyl)-7-hydroxycoumarin (HFC), that carry
no C3 substitution, by the recombinant enzymes were also
measured (Figure 5).
The human UGTs screen revealed that all six newly
synthesized C3 substituted 7-hydroxycoumarins were glucur-
onidated by UGT1A10 more rapidly than by other UGT forms.
Furthermore, 2, 4, 5, and 6 were selective for UGT1A10, as
other UGTs catalyzed their glucuronidation at very low rates.
The remaining two new substrates, 1 and 3, were
glucuronidated, in addition to UGT1A10, also by UGT1A1,
at rates of about 40% and 20%, respectively, of the
corresponding UGT1A10 rate (Figure 5). The glucuronidation
profiles of the new derivatives differed significantly from the
control substrates, 7-hydroxycoumarin and HFC, which were
glucuronidated primarily by UGT1A6 (7-hydroxycoumarin), or
UGT1A6 and UGT1A10 (HFC), as well as by few other UGTs
at lower rates (Figure 5).
In addition to recombinant UGTs, the glucuronidation rates
of all the new C3 7-hydroxycoumarin derivatives, along with 7-
hydroxycoumarin and HFC, were measured in human liver
microsomes (HLM) and human intestinal microsomes (HIM).
The results showed that all the new compounds were
glucuronidated by HIM at higher rates than by HLM (Figure
6). Furthermore, 2, 4, and 6 were not glucuronidated by HLM
at all, or only at very low rates, whereas 3 and 5 were
Figure 5. Glucuronidation of C3-substituted 7-hydroxycoumarins by human UGTs. Glucuronidation was determined at 10 μM aglycone
concentration.
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conjugated by HLM to about 20−25% of the rate exhibited by
HIM. Compound 1 was glucuronidated by HLM at about 40%
of the corresponding rate in HIM (Figure 6). Kinetics of
compound 6 glucuronidation confirmed that glucuronidation is
more specific in intestinal than hepatic microsomes, as its Km
value was 82 (49−115) μM and Vmax 4.0 (2.6−5.4) μmol/
(min* g prot) in human hepatic microsomes and its Km value
was 12 (8.8−15) μM and Vmax 3.5 (2.9−4.0) μmol/(min * g
prot) in human intestinal microsomes. Adding albumin to the
incubation mixture increased both Km and Vmax values in
instestinal microsomes. In sharp contrast to glucuronidation of
the new 7-hydroxycoumarin derivatives, the “parent com-
pound” 7-hydroxycoumarin, as well as HFC, were glucur-
onidated to much higher rates by HLM than by HIM (Figure
6).
Effect of H210 to M210 Mutation on UGT1A10
Activity. The developed model, by being explicit about the
role of certain key UGT1A10 residues in the binding of the
designed 7-hydroxycoumarin derivatives, also allowed testing it
by mutagenesis. Hence, we prepared mutant 1A10-H210M, a
mutant of UGT1A10 in which H210 was changed to
methionine, the corresponding residue in UGT1A1. The
mutant was expressed in insect cells, similarly to all the other
recombinant UGTs that were used in this study, and its activity
toward the new 7-hydroxycoumarin derivatives was tested. This
was combined with kinetic analyses of the glucuronidation of
these compounds by both UGT1A10 and UGT1A10-H201M,
side by side (Figure 7 and Table 1). The results demonstrated
clear effects of the mutation on the glucuronidation kinetics of
most compounds. A decrease of Vmax occurred in all but 2 and
6, in which the Km values were considerably increased (Table
1). Changes in the Km values of the other compounds were
variable; however, an increase in the case of HFC, no change
for 5, and a decrease in 1, 3, and 4 (Table 1).
■ DISCUSSION
In this study, we constructed predictive homology models for
the human UGT1A enzymes in order to design selective
substrates for them. The models indicated several key
characteristics that differ among the active sites of individual
UGT1A enzymes. These differences were exploited for the
design and synthesis of six new 3-substituted 7-hydroxcoumarin
derivatives. All the new compounds were good substrates for
UGT1A10 and four of them, namely 2, 4, 5, and 6, were
selective substrates for this UGT (Figure 5). Among the clear
advantages of these new 7-hydroxcoumarin derivatives as
UGT1A10 substrates are their extensive fluorescence and
simple synthesis from low-cost starting materials that make
Figure 6. Glucuronidation of C3-substituted 7-hydroxycoumarins by
human intestinal and hepatic microsomes. Glucuronidation was
determined at 10 μM aglycone concentration.
Figure 7. Michaelis−Menten kinetics of UGT1A10 (open circle) and UGT1A10 mutant (closed circle) catalyzed 7-hydroxyl glucuronidation for the
3-substituted 7-hydroxycoumarins (1−7 and HFC). The data are from one experiment, and the analyzed data are shown in Table 1.
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them suitable for quick and convenient activity measurements
in a high-throughput format.
Currently, no high-resolution, or even low-resolution,
structure of a full-length UGT is available from X-ray
crystallography or cryo-electron microscopy. Although their
3D-model construction is challenging, homology models of
UGT1A1, 1A3, 1A4, 1A5, 1A6, 1A7, 1A8, 1A9, and 1A10 were
constructed in this study. These models suggested that the
active site of UGT1A10 is sufficiently different from the other
UGTs to enable design and synthesis of selective substrates for
it.
We had two goals in designing these substrates: they should
be selective for UGT1A10, and determination of their
glucuronidation should be based on easily measurable
fluorescence change during the assay. As a starting point, the
7-hydroxycoumarin scaffold was selected, since it is a common
UGT substrate and its derivatives have intense fluorescence.44
In addition, 7-hydroxycoumarin and 7-hydroxy-4-
(trifluoromethyl)coumarin have both been shown to be
glucuronidated by several different UGTs.25 The hydroxyl
group of 7-hydroxycoumarin was oriented toward the UDPGA
in the active site of the UGT1A10 model, indicating that there
is space in the active site for an additional six or five ring
substituent at position C3 of the 7-hydroxycoumarin scaffold
(Figure 2). Thus, we synthesized six new UGT1A10 substrates,
all of which were 7-hydroxycoumarin derivatives with various
substituents at position C3 of the coumarin scaffold.
All of the new 7-hydroxycoumarin derivatives are highly
fluorescent, and their fluorescence decreases upon enzymatic
glucuronidation (see Figure 4 for an example with compound
6). A concern in these assays was nonlinearity of the
fluorescence at substrate concentrations above 20 μM.
However, fluorescence changes of these substrates were
selective, sensitive and quantitative enough for measurements
below this concentration limit, as the amount of UGT1A10
enzyme could be adjusted to yield linear glucuronidation rates.
The selectivities of the 7-hydroxycoumarin derivatives for
UGT1A10 differed substantially. While some of them, such as
2, 4, and 6, were highly selective, others, like 1 and 3, were also
glucuronidated by UGT1A1 at considerable rates (Figure 5).
Previous studies have shown that fluorescent derivatives of N-
butyl-4-phenyl-1,8-naphthalimide are UGT1A1 selective sub-
strates.45
Since UGT1A10 is an extrahepatic enzyme expressed at high
levels in the intestine,11 the results obtained with recombinant
UGTs could be tested with HLM and HIM. Although these
microsomal preparations contain several different UGTs each,
HLM lacks a functional UGT1A10 while HIM contains it.11
Indeed, the glucuronidation rates in HLM of 4 and 6, as well as
2, were very low or below the detection limit. Glucuronidation
of 1, 3 and 5 took place in HLM at rates up to 40% of the rates
in HIM (Figure 6). These results also suggest which of the new
compounds would be most useful for studies on UGT1A10
activity in samples from human tissues that express or may
express this enzyme. The current results point at 2, 4 and 6 as
good candidates, 2 due to the lack of detectable activity in
HLM, 4 based on the combination of high rate with high
selectivity, and 6 due to its high selective fluorescence intensity
(Figure 6 and Supplementary Figures S1 and S2). It may be
added here that we recently reported that the commonly used
commercial UGT1A10 has low activity.13 In this study we have
used the UGT1A10-H preparation, not the commercial
UGT1A10. Researches should not expect to get similar resultsT
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to those reported here for UGT1A10 when working with the
commonly used commercial UGT1A10. On the other hand,
experiments with commercial HIM and HLM are expected to
reproduce the current results.
It is interesting to understand why 6 has a remarkably lower
(less than 30%) intrinsic glucuronidation clearance (Vmax/Km)
by UGT1A10 than the other new 7-hydroxycoumarin
derivatives, 1−5 (Table 1). Examination of the substituents at
C3 suggests that 6 with a triazole derivative at C3 was
glucuronidated less efficiently than derivatives containing
hydrophobic or other types of hydrophilic substituents. The
reason for this could be that the triazole causes stronger
interactions than the other substituents in the active site of
UGT1A10, resulting in slower release of the formed
glucuronide.
The present modeling work indicates specific residues that
are expected to lead to substrate selectivity of UGT1A10. We
have tested one of the predicted residues, H210, by changing it
to M210, the corresponding residue in UGT1A1, expressed the
mutant UGT1A10-M210 and studied the glucuronidation
kinetics of all the new compounds by both the wildtype (i.e.,
UGT1A10-H210) and mutant enzymes. The results revealed
changes in the Km and/or Vmax values of the glucuronidation
kinetics of all the compounds, but with clear differences among
them (Figure 7 and Table 1). Another unexpected observation
was the effect of the mutation on HFC glucuronidation rate,
which may suggest that the effect of the mutation is larger than
expected by the model, or that substrate(s) binding by
UGT1A10 (also) involves an induced fit mechanism.
In conclusion, in this study, 3D molecular models of the
UGT1As were constructed and used for the design and
synthesis of six new fluorescent UGT substrates. A new
multiwell-based method that takes advantage of the fluo-
rescence of the compounds and their fluorescence decrease
upon glucuronidation was established to measure glucuronida-
tion rates. Of the new compounds, 4-(dimethylamino)phenyl
(4) and triazole (6) C3-substituted 7-hydroxycoumarins
appeared to be the most selective substrates for UGT1A10,
an important and often underestimated extrahepatic human
UGT. It is concluded that the selectivity of the new coumarin
derivatives for UGT1A10 depends on the chemical character of
their substituent at C3. These new compounds should enable
better, faster, and easier determination of UGT1A10 activity in
tissues than was earlier possible. In addition, their further
chemical modification could stimulate the development of new
tools to explore the active site of different UGT enzymes.
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